Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.
To accelerate IL-2RB-related research, Creative Biolabs offers a wide range of high-quality anti-IL2RB recombinant antibodies. These antibodies are produced using advanced technology to ensure high specificity, stability, and efficacy. As a result, they are valuable tools for researchers and developers working on targeted cancer therapies.
Essential for immune system control, the Interleukin-2 receptor beta chain (IL2RB) is linked to a spectrum of disorders when dysfunctional. In autoimmune diseases, IL2RB's loss might cause the immune system to target normal tissues. Moreover, several tumors include this receptor, which influences the spread of malignant cells. IL2RB also affects the immune response to infections like TB. Development of focused therapies and improvement of patient care depend on an understanding of the many roles IL2RB performs.
Interleukin-2 receptor subunit beta; CD122; IL15RB; P70-75; IMD63; IL2RB.
The interleukin 2 receptor, which is involved in T cell-mediated immune responses, is present in 3 forms with respect to ability to bind interleukin 2. The low affinity form is a monomer of the alpha subunit and is not involved in signal transduction. The intermediate affinity form consists of an alpha/beta subunit heterodimer, while the high affinity form consists of an alpha/beta/gamma subunit heterotrimer. Both the intermediate and high affinity forms of the receptor are involved in receptor-mediated endocytosis and transduction of mitogenic signals from interleukin 2. The protein encoded by this gene represents the beta subunit and is a type I membrane protein. The use of alternative promoters results in multiple transcript variants encoding the same protein. The protein is primarily expressed in the hematopoietic system. The use by some variants of an alternate promoter in an upstream long terminal repeat (LTR) results in placenta-specific expression.
Creative Biolabs provides a large range of recombinant anti-IL2RB antibodies that have been carefully engineered to have excellent affinity and remarkable specificity. From basic scientific research to cutting-edge medicinal developments, our many kinds of antibodies are meant to enable a wide spectrum of research uses. These antibodies serve as powerful tools to advance immunology, cancer biology, and allied sciences and help to build next-generation therapeutic solutions by using the advanced platform.
Table 1. Featured anti-IL2RB recombinant antibody products at Creative Biolabs.
Cat. No. | Product Name | Target Species | Host Species | Applications |
TAB-639LC | Human Anti-IL2RB Recombinant Antibody (TAB-639LC) | Human | Human, humanized antibody | ELISA, FC, FuncS |
TAB-640LC | Human Anti-IL2RB Recombinant Antibody (TAB-640LC) | Human | Human, humanized antibody | ELISA, FC, FuncS |
TAB-637LC | Mouse Anti-IL2RB Recombinant Antibody (TAB-637LC) | Human, Monkey | Mouse IgG1, κ | ELISA, FC, FuncS |
TAB-638LC | Mouse Anti-IL2RB Recombinant Antibody (TAB-638LC) | Human, Monkey | Mouse IgG2b, κ | ELISA, FC, FuncS |
TAB-425CL | Anti-Human IL2RB Recombinant Antibody (MiK-Beta-1) | Human | Humanized antibody | WB, ELISA, etc. |
Creative Biolabs offers an extensive array of recombinant antibodies that specifically target IL2RB, expertly developed and rigorously validated for quality. Our state-of-the-art laboratory and experienced researchers are devoted to creating each antibody with accuracy, assuring precise targeting of IL2RB. With extensive validation methods in place, we guarantee that our antibodies demonstrate great specificity, robust binding affinity, and dependable performance across a broad variety of research applications, making them crucial tools for scientists in the field.
Fig.1 WB analysis of anti-IL2RB antibody
(Cat# TAB-425CL, Creative Biolabs).
Fig.2 ELISA analysis of anti-IL2RB antibody
(Cat# TAB-425CL, Creative Biolabs).
Creative Biolabs offers a reliable range of high-quality anti-IL2RB antibodies that are carefully made utilizing state-of-the-art genetic engineering techniques. Every antibody is meticulously created to guarantee improved effectiveness and dependability for a range of research uses.
Featured Anti-IL2RB Recombinant Antibody Production Platforms
Fig.3 Milligram-scale anti-IL2RB recombinant antibody production.
Fig.4 Gram-scale anti-IL2RB recombinant antibody production.
To meet the various demands of researchers throughout the world, Creative Biolabs provides a comprehensive range of high-quality anti-IL2RB recombinant antibodies in a variety of forms.
Fig.5 Full-length anti-IL2RB recombinant antibody production and modalities.
Table 2. Public drug targeting IL2RB.
Company | Research phase | Classification | Condition |
Cerimon Novartis (Originator) |
Launched - 1998 | Chimeric Monoclonal Antibodies |
Cytokine release syndrome Immunosuppression Inflammatory bowel disease Transplant rejection Transplant rejection, kidney Ulcerative colitis Uveitis |
Biogen (Originator) Roche (Originator) Shionogi |
Launched - 1992 |
Cancer Immunotherapy IL-2 Polypeptides, from 41 AA Recombinant proteins |
Angiosarcoma Cancer, colorectal, metastatic |
Abbott AbbVie Biogen Biogen Idec (Biogen) National Cancer Institute National Eye Institute (NEI) PDL BioPharma (Originator) Protein Design Labs (PDL BioPharma) Roche UCB |
Withdrawn - 2018 |
Cancer Immunotherapy Humanized Monoclonal Antibodies |
Asthma Diabetes type 1 Eye Disorders Hodgkin lymphoma Immunosuppression Leukemia-lymphoma, adult T-cell Multiple sclerosis Multiple sclerosis, relapsing-remitting Psoriasis Transplant rejection Transplant rejection, heart Transplant rejection, kidney Ulcerative colitis Uveitis |
Biotest (Originator) ElsaLys Biotech Jazz Pharmaceuticals OPi (Jazz Pharmaceuticals) |
Pre-Registered | Murine Monoclonal Antibodies | Graft-versus-host disease |
Mabpharm Mabtech (Sinomab) Sinomab (Originator) Sorrento Therapeutics TNK Therapeutics |
Phase III |
Chimeric Monoclonal Antibodies Follow-on Products |
Transplant rejection |
Second Xiangya Hosp Central South Univ (Originator) | Phase II |
IL-2 Polypeptides, from 41 AA Recombinant proteins |
Pemphigus vulgaris Urticaria |
Lilly Nektar Therapeutics (Originator) |
Phase II |
IL-2 Pegylated Drugs Polypeptides, from 41 AA Recombinant proteins |
Alopecia areata Atopic dermatitis Autoimmune disease Crohn's disease Graft-versus-host disease Plaque psoriasis Rheumatoid arthritis Systemic lupus erythematosus Ulcerative colitis |
Bioniz Therapeutics (Equillium) Equillium (Originator) |
Phase II |
Pegylated Drugs Peptides |
Alopecia areata Atopic dermatitis Cutaneous T-cell lymphoma HTLV-1-associated myelopathy-tropical spastic paraparesis Large granular lymphocytic leukemia Lymphocytic leukemia Vitiligo |
University of California Los Angeles (Originator) | Phase II | Transplant rejection | |
National Cancer Institute (Originator) | Phase II |
Fusion Proteins Immunotoxins Polypeptides, from 41 AA Toxins |
Chronic lymphocytic leukemia Cutaneous T-cell lymphoma Hairy cell leukemia Leukemia Lymphoma Melanoma |
(Disclaimer: The information in this table is just for knowledge sharing and not for marketing or sales purposes.)
As an established leader in the antibody industry, Creative Biolabs consistently integrates innovative technologies and specialized knowledge to enhance the quality and efficacy of our products. If you're seeking dependable IL2RB antibody solutions, don't hesitate to reach out to us for further information and assistance.